Dr. Jaewoo Kang

Chief Executive Officer & Founder

• - Leading expert in AI-driven drug discovery.
• - Professor of Computer Science at Korea University (since 2006),
  previously at North Carolina State University.
• - Developed BioBERT, the most-cited biomedical AI language model (>7,000 citations).
• - Secured multiple AI drug discovery challenge wins and led collaborations with AstraZeneca
  on AI-driven frameworks.
• - Ph.D. in Computer Science from the University of Wisconsin-Madison.

Dr. Sunkyu Kim

Director of AI Research

• - Expert in AI-driven drug discovery & computational biology.
• - Led AI initiatives in bioinformatics, pharmacogenomics, and cheminformatics.
• - Winner of BioCreative (2021), IDG-DREAM (2019), and NCI-CPTAC DREAM (2018).
• - Former Research Professor at Korea University.
• - Ph.D. in Computer Science & Engineering from Korea University.

Dr. Kwang-Ok Lee

Chief Scientific Officer

• - 30+ years in drug discovery & medicinal chemistry.
• - Former leader at Hanmi Pharmaceutical, contributing to Poziotinib, Olmutinib, and BTK inhibitor HM71224.
• - Led R&D at Bukwang and Yungjin Pharmaceuticals.
• - Ph.D. in Medicinal Chemistry from Seoul National University.

Dr. Ho-Jeong Lee

Chief Biology Officer

• - Expert in translational research & non-clinical drug evaluation.
• - Former CSO at PLATBIO and General Executive Director at Hanmi Pharmaceutical.
• - Preclinical research leader on Belvarafenib, Poziotinib, and Olmutinib.
• - Ex-postdoctoral fellow at MD Anderson Cancer Center, focusing on drug repositioning.
• - Ph.D. in Biotechnology from Korea University.

Jin-Kwan Kim

Chief Discovery Officer

• - 20 years in medicinal chemistry & small molecule drug development.
• - Former Project Leader at Dong-A ST, leading kinase and epigenetic inhibitor programs, including a $565M MERTK inhibitor deal with AbbVie.
• - Expertise in target protein degradation, kinase/phosphatase targeting, and AI drug discovery.
• - Master’s in Pharmaceutical Chemistry from Seoul National University.

Soojung Lee

Chief Strategy Officer

• - Biotech executive with expertise in pharmacoeconomics, licensing, and business strategy.
• - Former Deputy BD Leader at Peptron.
• - Co-founder of G2GBIO, leading global licensing & clinical development.
• - Former BD & Clinical Development Lead at J2H Biotech.
• - Master’s in Genetic Engineering from Seoul National University; Executive MBA from KAIST.

Jongseung Kim

• - Professor, Department of Chemistry, Korea University (2007–present)
• - Director, Creative Research Initiative Project (2009–present)
• - Member, Korea Academy of Science and Technology (2014–present)
• - Ph.D. in Organic Chemistry, Texas Tech University, USA
• - Research Interests: Cancer (CRC, TNBC), Neurodegeneration

Kyonghwa Park

• - Professor, Oncology and Hematology, Anam Hospital, Korea University (2007–present)
• - Member, Korean Association of Internal Medicine, Korean Cancer Association, AACR
• - Ph.D., College of Medicine, Korea University (2005)
• - M.D., College of Medicine, Korea University (1998)
• - Research Interests: Cancer (Breast, Gynecologic, Urologic)

Sangjoon Shin

• - Professor, Department of Internal Medicine, College of Medicine, Yonsei University (2013–present)
• - Member, Korean Cancer Association, Korean Society of Medical Oncology, ASCO, AACR, ESMO
• - Ph.D., College of Medicine, Yonsei University (2011)
• - M.D., College of Medicine, Yeungnam University (1998)
• - Research Interests: Cancer (Colorectal, Melanoma, Urologic)